Latest News for PRPO
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
PRPO's second-quarter 2026 revenue momentum strengthens on higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation.
Precipio, Inc. (PRPO) Q2 2026 Earnings Call Transcript
Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position
Precipio, Inc. (NASDAQ: PRPO - Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $25.12 and traded as low as $20.20. Precipio shares last traded at $21.65, with a volume of 21,130 shares trading hands. Analysts Set New Price Targets A number of
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRPO.
U.S. House Trading
No House trades found for PRPO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.